Many false trails have been followed over the years in attempts to associate schizophrenia with biochemical anomalies. Recently it has been found that there is a close correlation between the efficacy of certain neuroleptic agents in the management of the disease and their ability to block CNS receptor sites activated by dopamine. It is suggested that this may be a clue to one of many genetic bases of schizophrenia.